Phase II study of combination therapy with S-1 and cetuximab in patients with KRAS wild-type unresectable colorectal cancer who had previously received irinotecan, oxaliplatin, and fluoropyrimidines (KSCC0901).
Kazuma Kobayashi; Yasunori Emi; Yoshihiro Kakeji; Takao Takahashi; Eiji Oki; Yoshito Akagi; Akihito Tsuji; Yasuhiro Kodera; Kazuhiro Yoshida; Hideo Baba; Mitsuo Shimada; Yutaka Ogata; Mototsugu Shimokawa; Shoji Tokunaga; Shoji Natsugoe; Yoshihiko Maehara
JOURNAL OF CLINICAL ONCOLOGY 30 (15) 0732-183X 2012/05
[Refereed]